|
STICKY:
Healio/HCV Updates
(
1 2
)
(Preview)
http://www.healio.com/infectious-disease/hepatitis-c
|
Tig
|
87
|
11166
|
|
|
|
|
STICKY:
HCV News Updates 2019
(Preview)
There seems to be a lot of articles available now, so I thought a section to add miscellaneous items we find across the web, might be useful. Feel free to add information that is accurate and helpful for those seeking it. Always credit the source. Thanks! Drugs. com Hep C News
|
Tig
|
0
|
203
|
|
|
|
|
STICKY:
HCV Advocate Monthly Report
(Preview)
Current reports from the HCV Advocate Drug Pipeline and Monthly report. Good stuff! August 1, 2017 Aug 2017 Eblast Newsletter
|
Tig
|
21
|
4354
|
|
|
|
|
STICKY:
Technivie Monograph
(closed)
(Preview)
Technivie Monograph (Manufacturer's detailed package insert)
|
Tig
|
0
|
2531
|
|
|
|
|
STICKY:
Daklinza Monograph
(closed)
(Preview)
Daklinza Monograph (Manufacturers detailed package insert)
|
Tig
|
0
|
2473
|
|
|
|
|
STICKY:
MAVIRET/MAVYRET Monograph (glecaprevir/pibrentasvir)
(closed)
(Preview)
Maviret/Mavyret Monograph
|
Tig
|
0
|
3075
|
|
|
|
|
STICKY:
Zepatier Monograph
(closed)
(Preview)
Zepatier Monograph (Manufacturers detailed package insert)
|
Tig
|
0
|
2446
|
|
|
|
|
STICKY:
Viekira Pak - Viekira XR Monograph(s)
(closed)
(Preview)
Abbvie Pharmaceutical has improved the original Viekira Pak formulation and has included the timed release product called Viekira XR. That description and the original formulation of Viekira Pak follow. (Manufacturers detailed package insert) Viekira XR Monograph Viekira Pak Monograph
|
Tig
|
0
|
2598
|
|
|
|
|
STICKY:
Epclusa Monograph
(closed)
(Preview)
Detailed manufacturers information (package insert) on Epclusa Epclusa Monograph
|
Tig
|
0
|
2476
|
|
|
|
|
STICKY:
Vosevi Monograph
(closed)
(Preview)
VOSEVI Monograph (Manufacturers detailed package insert)
|
Tig
|
0
|
2988
|
|
|
|
|
STICKY:
Hepatitis C Medication Review & Update 2017
(closed)
(Preview)
How is hepatitis C treated?Hepatitis C virus is treated with all-oral medications. These pills, called antiviral medications, are usually taken once per day. These antiviral medications are extremely good at attacking the virus and preventing it from multiplying.Antiviral medications wer...
|
Tig
|
0
|
2584
|
|
|
|
|
STICKY:
HARVONI Monograph
(closed)
(Preview)
Harvoni Monograph -Manufacturers Insert
|
Tig
|
0
|
4292
|
|
|
|
HepVu Updates
(Preview)
Hello, I've been receiving these articles from HepVu and wanted to pass along their website. It's a very informative website and organization. I recommend you take a moment and look around the information provided. The infection rate by state is an interesting map. We've got a long way to go before w...
|
Tig
|
0
|
90
|
|
|
|
|
Hep A Food Warning Dec.2019
(Preview)
I received notice of a Hepatitis A outbreak in the USA, resulting from blackberries. Please read! Hep A Warning
|
Tig
|
0
|
103
|
|
|
|
|
What is Daclatasvir used for?
(Preview)
Uses. Daclatasvir is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Daclatasvir should never be used without sofosbuvir. Daclatasvir and sofosbuvir may also be used with another antiviral medica...
|
emilyjones
|
0
|
135
|
|
|
|
|
AASLD & IDSA HCV Treatment Updates/Guidelines 2019
(Preview)
The latest recommendations and an interactive website for inquisitive minds! Updated information available. HCV Guidelines
|
Tig
|
0
|
171
|
|
|
|
|
New Contenders?? NS5A Ruzasvir and NS5B MK-3682
(Preview)
Another "new?" NS5A - "Ruzasvir" - Info from drug study discussed at recent Nov 2106 Boston Meeting.We have heard a lot about Zepatier (elbasvir/ grazoprevir) a NS5A and a NS3/4A respectively (given with or without riba, and sometimes with sof), but I (personally) did not know about this (new to m...
|
Canuck
|
8
|
2639
|
|
|
|
|
GT3's - (and more so, maybe "certain" GT3 sub-types) - perhaps why we have most often been considered "hard to treat"
(Preview)
Published in GastroenterologyJournal Scan / Research · May 20, 2019Resistance Analysis of Genotype 3 HCV Indicates Subtypes Inherently Resistant to Nonstructural Protein 5A InhibitorsHepatology (Baltimore, Md.)TAKE-HOME MESSAGEThis is an interesting study wherein the authors eva...
|
Canuck
|
2
|
379
|
|
|
|
|
Up-surge of Hep A in California
(Preview)
California health officials battle state's largest hepatitis A outbreak in 2 decadesHelio - July 21, 2017The California Department of Public Health is working with local health officials in San Diego and Santa Cruz counties to contain the state's largest hepatitis A outbreak in 2 decades.As of J...
|
Canuck
|
36
|
4441
|
|
|
|
|
HCC Detection - Using AFP, AFP-L3 and DCP
(Preview)
We have discussed the use of AFP's (many times, all over this site) but of late in particular about how an AFP may be used to possibly herald other kinds of cancers developing, aside from liver cancer, and it lead us to discuss not only the good ole familiar AFP, but the less US-used one, the AFP-L3 (this o...
|
Canuck
|
1
|
219
|
|
|
|
|
Significant A1C reduction after SVR
(Preview)
This is very good news for those of us keeping an eye on our blood glucose levels! SVR brings improvements in areas we might not realize. It takes time to see some of these changes, but knowing it happens, is good news for all! A1C Reductions
|
Tig
|
1
|
329
|
|
|
|
|
Cure of hepatitis C
(Preview)
I ran my own company for several years, and I was always on the go. Sometime around 2010 or later, I began to feel tired all the time. I went to doctors, and they kept ordering lab tests, such as checking for diabetes. They couldnt find anything wrong with me for a year or two, so eventually I stopped going t...
|
jagad001
|
6
|
506
|
|
|
|
|
BP Med - Losartan (and recalls, and fibrosis)
(Preview)
I think it was "dharmabum" who first raised the early alarm about some sort of "recall" going on with a med (that I think she was on), Losartan (perhaps it was some other Losartan formula name she mentioned), but I do believe this Losartan drug was the one she referred to and was concerned about (I looked...
|
Canuck
|
0
|
407
|
|
|
|
|
Region's 1st HCV heart-transplant is Cured WOW
(Preview)
HEY NEW MEMBERS, IF HE CAN DO IT, SO CAN YOU! WE'VE MADE SO MUCH PROGRESS! NEWS RELEASEJanuary 16, 2019For immediate releaseRegions 1st hepatitis C heart-transplant recipient is curedAnacortes, Wash., man opted into UW Medicine protocol to receive infected donor heart and then had virus eradi...
|
Cheddy
|
2
|
579
|
|
|
|
|
Dacla and Asunaprevir
(Preview)
Not that in North America we have seen Dacla (a NS5A) and Asunaprevir (a NS3/4A) being used as a double, but in Japan they have made use of this double. Multiple Japanese studies have fairly recently been coming out about the prevalent use of this combo and various notes they are making about it. This st...
|
Canuck
|
0
|
564
|
|
|
|
|
HCV: Explained 2018
(Preview)
I found this recent article on our favorite topic, HCV. I found it to be a good description of it and the many issues that accompany it. It’s easy to understand and could be a good tool for us to present when asked about the disease. See what you think. I give it a 9 out of 10... Everything You Need to Know: HCV...
|
Tig
|
0
|
718
|
|
|
|
|
Shortening HCV Treatment Courses
(Preview)
From "Contagion Live - Infectious Diseases Today": ARTICLE Hepatitis C Treatment Time Could Be Cut in Half in Some Patients: A Proof of Concept Study NOV 14, 2018 | EINAV KEET A personalized medicine technique may shorten the duration and reduce the cost of treatment for hepatitis C virus infecti...
|
Canuck
|
0
|
760
|
|
|
|
|
Organ Donors
(Preview)
http://time.com/4996657/heart-transplant-hepatitis-c/
|
dharmabum
|
5
|
1843
|
|
|
|
|
AASLD/IDSA release updated HCV treatment guidelines
(Preview)
The AASLD and IDSA HCV Guidance Panel has released updated guidelines for the treatment of hepatitis C virus infection, according to newly published data in Hepatology. You will note that they continue to recommend the use of 12 weeks of Sovaldi/Peg Interferon/Ribavirin in GT 3's that are able to...
|
Tig
|
1
|
1614
|
|
|
|
|
Liver Transplant Article
(Preview)
So, this article/take-home message, about the study (and the study itself) I found interesting - and, oh of course, they just had to study the costs savings! The part that was interesting to me was that group of liver transplant people who were studied and followed between 1998 and 2015, who WERE tole...
|
Canuck
|
0
|
667
|
|
|
